[RECORDED WEBINAR] The Future of Pharmaceutical Pricing

Listen in to hear more about the future of pharmaceutical pricing, focusing on the three key issues of affordability, evidence and value attribution. During this on demand session, you will hear more about:


  • Challenges and solutions in both emerging and developed markets
  • Ability to pay versus willingness to pay for high value/ high cost combinations such as “Cancer Stacks”, advanced therapy medicinal products (ATMPs), and gene, tissue and cell therapies in rare diseases
  • Differential pricing, managed entry agreements, risk sharing, and financial services models


  • Challenges and solutions due to both absence of data and over-abundance of data
  • Single-arm studies, uncontrolled/non-comparative studies and tumor agnostic licensure
  • Greater acceptability of multi-source real-world data by HTA

Value Attribution

  • Challenges and solutions in Connected Health
  • When disease management is delivered through biomarker detection (Dx), informed by digital monitoring and analytics (algorithms and apps), and treated using combinations of products (Rx) from different manufacturers  
  • Value and revenue attribution – the next big challenge in pricing   

Consumer & Shopper